A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cellsPrevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.Prominin-2 is a cholesterol-binding protein associated with apical and basolateral plasmalemmal protrusions in polarized epithelial cells and released into urineLoss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.Rapamycin extends murine lifespan but has limited effects on aging.Association of Oesophageal Varices and Splanchnic Vein Thromboses in Patients with JAK2-Positive Myeloproliferative Neoplasms: Presentation of Two Cases and Data from a Retrospective Analysis.Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell.Mesenchymal stem cells can be differentiated into endothelial cells in vitro.Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.Comparison of flow cytometry and laser scanning cytometry for the analysis of CD34+ hematopoietic stem cells.Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis.PET/MRI Imaging in High-Risk Sarcoma: First Findings and Solving Clinical ProblemsTherapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT.Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".Support of unrelated stem cell donor searches by donor center-initiated HLA typing of potentially matching donors.A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays.Gene and haplotype frequencies for the loci hLA-A, hLA-B, and hLA-DR based on over 13,000 german blood donors.Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia.Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitorsPatients' perspectives on palliative chemotherapy of colorectal and non--colorectal cancer: a prospective study in a chemotherapy- experienced populationPrediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST).HLA-C expression levels define permissible mismatches in hematopoietic cell transplantationEGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinomaRegional HLA differences in Poland and their effect on stem cell donor registry planning.MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cellsBe smart against cancer! A school-based program covering cancer-related risk behavior¹⁸F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia
P50
Q27345360-38062C5F-8B5F-4C22-B982-21DB35EA3E2DQ27824861-D005879B-4230-408B-98F8-0AFF3C938CF2Q27851579-2752AFBC-15B2-4BE3-B219-560CDB9967DBQ27853319-8225B231-AA42-4E3C-8654-A8E3BAAD3E6FQ28508316-2F5B2C23-6A7F-4A29-B2EE-64A3118507D6Q30313615-31888D5E-903F-43F2-86C8-401561FFB9DDQ30315977-68CF74C6-D328-425C-A1B7-3DF70D75996CQ30316874-136E5B14-50ED-4D79-A76A-23BB11F7A121Q30541884-42296E2E-C3FD-4E99-83CF-E1D4C8771644Q30658101-3BFFC483-FBCE-4AF0-AA3F-E32122EF13ECQ30881604-80548716-C4D9-4FCD-94DB-77312CB01CE5Q31063600-1e59c1c7-41b1-40b5-83d0-0f71abc14d27Q31114679-612A4635-E20A-40AD-A90B-CEBE0736B63BQ33197197-33d7794e-403b-5c70-e5fb-b7b2a3606e35Q33321374-15672BFE-9B34-4E3B-A3B7-34BD69290392Q33356327-3FF1B08B-3264-422D-AC61-6C6F31FB862BQ33402744-252F23CD-2F8E-4FAC-8453-0BBFA5455F96Q33404483-466E415E-365B-4D38-A57D-419FF27DF249Q33409020-D53FDE0D-F611-457B-89AA-F1705B9508CCQ33424261-9D1B4DD2-5697-440F-AB9D-78B84CE4891DQ33432481-8FE1B731-AF70-465D-9EDD-3F1970663781Q33746730-B97AE0AD-B1AC-4524-BA7D-77E3DBA5C122Q33761755-0E50C5B5-0B33-476B-B332-DA8AB399E525Q33916233-53B4055B-4817-4C36-A258-D047D10D05BBQ34056156-1A919D37-1810-4665-8D80-6D7056CAEBF1Q34146721-7E23A0AD-30C5-451E-B16B-0D8599DC3A3EQ34167813-1F36A443-8EC4-4952-8F6F-0DD231741E4CQ34310541-AC05A5E0-A378-4A7B-B92F-8A852C6E91B5Q34523534-7465A6F9-E914-45D6-8FD7-A8EBD768ED9DQ34541052-FDA11BC1-FACF-4080-A2E9-85B3EA4DA376Q34566158-450E6063-0269-443F-B72B-29E6AE6A2FD4Q34580422-780A147C-1638-4631-9DEF-F1EE5639C49FQ34634662-FC7BD62A-3B59-4B06-9C24-BDFB431F466CQ34649548-9BBC280B-1007-4370-A178-DBBDA84EE5D2Q34737555-33C094FF-26E3-4361-BEE1-9CA825BFD4B6Q34738001-503D8A75-A13F-4F21-A117-9BFCC28A2210Q34998868-BBE8B683-E9DE-471B-B136-33CF2785643EQ35105333-CCAEEF51-D2F0-4CF0-9BC8-78B6138AE9C4Q35155621-DD5C42B8-96AA-4197-8EC0-66E0BB0E6408Q35266033-0656CDE1-B356-45CB-8CE7-09AE780F3F04
P50
description
Duits hoogleraar
@nl
German physician
@en
German university teacher
@en-ca
German university teacher
@en-gb
Saksamaa ülikooli õppejõud
@et
deutscher Mediziner
@de
dochtúir Gearmánach
@ga
medico tedesco
@it
médecin allemand
@fr
profesor universitar german
@ro
name
Gerhard Ehninger
@ast
Gerhard Ehninger
@ca
Gerhard Ehninger
@da
Gerhard Ehninger
@de
Gerhard Ehninger
@en
Gerhard Ehninger
@es
Gerhard Ehninger
@fr
Gerhard Ehninger
@it
Gerhard Ehninger
@nds
Gerhard Ehninger
@nl
type
label
Gerhard Ehninger
@ast
Gerhard Ehninger
@ca
Gerhard Ehninger
@da
Gerhard Ehninger
@de
Gerhard Ehninger
@en
Gerhard Ehninger
@es
Gerhard Ehninger
@fr
Gerhard Ehninger
@it
Gerhard Ehninger
@nds
Gerhard Ehninger
@nl
prefLabel
Gerhard Ehninger
@ast
Gerhard Ehninger
@ca
Gerhard Ehninger
@da
Gerhard Ehninger
@de
Gerhard Ehninger
@en
Gerhard Ehninger
@es
Gerhard Ehninger
@fr
Gerhard Ehninger
@it
Gerhard Ehninger
@nds
Gerhard Ehninger
@nl
P1006
P214
P227
P1006
P106
P1412
P1559
Gerhard Ehninger
@de
P19
P21
P213
0000 0000 5810 8170
P214
P227
P31
P496
0000-0003-0056-0422
P569
1952-06-11T00:00:00Z
P735
P7859
viaf-80321759